NO944919L - Fremgangsmåte for å inhibere atrofi av huden eller vagina - Google Patents

Fremgangsmåte for å inhibere atrofi av huden eller vagina

Info

Publication number
NO944919L
NO944919L NO944919A NO944919A NO944919L NO 944919 L NO944919 L NO 944919L NO 944919 A NO944919 A NO 944919A NO 944919 A NO944919 A NO 944919A NO 944919 L NO944919 L NO 944919L
Authority
NO
Norway
Prior art keywords
vagina
skin
inhibiting atrophy
atrophy
inhibiting
Prior art date
Application number
NO944919A
Other languages
English (en)
Other versions
NO944919D0 (no
Inventor
George Joseph Cullinan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO944919D0 publication Critical patent/NO944919D0/no
Publication of NO944919L publication Critical patent/NO944919L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Det er beskrevet en fremgangsmåte for inhibering av atrofi av huden eller vagina Innbefattende administre- ring til et menneske som har behov for dette av en effektiv mengde av en forbindelse som har formelen OCH2CH2 ¿R1 (D hvori R1 og R3 uavhengig av hverandre er hydrogen, -CH3, O O II II -C-(Ci-Cb alkyl), eller -C-Ar, hvor Ar er eventuelt substituert fenyl; R2 er valgt fra gruppen bestående av pyrrolldin, heksametylenamlno og plperidlno; eller et farmasøytisk akseptabelt salt eller solvåt derav.
NO944919A 1993-12-21 1994-12-19 Fremgangsmåte for å inhibere atrofi av huden eller vagina NO944919L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/171,087 US5461064A (en) 1993-12-21 1993-12-21 Methods of inhibiting atrophy of the skin and vagina

Publications (2)

Publication Number Publication Date
NO944919D0 NO944919D0 (no) 1994-12-19
NO944919L true NO944919L (no) 1995-06-22

Family

ID=22622468

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944919A NO944919L (no) 1993-12-21 1994-12-19 Fremgangsmåte for å inhibere atrofi av huden eller vagina

Country Status (17)

Country Link
US (2) US5461064A (no)
EP (1) EP0664124B1 (no)
JP (1) JPH07215860A (no)
KR (1) KR950016732A (no)
CN (1) CN1108097A (no)
AU (1) AU699948B2 (no)
CA (1) CA2138511A1 (no)
CZ (1) CZ321594A3 (no)
DE (1) DE69426690T2 (no)
ES (1) ES2153851T3 (no)
HU (1) HUT71221A (no)
IL (1) IL112041A0 (no)
NO (1) NO944919L (no)
NZ (1) NZ270173A (no)
PH (1) PH31600A (no)
RU (1) RU2143897C1 (no)
ZA (1) ZA9410078B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
JPH08510451A (ja) 1993-05-13 1996-11-05 ネオルックス コーポレイション 異常増殖性平滑筋細胞に関連した病因の予防及び治療
US5811120A (en) * 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5972383A (en) * 1994-03-02 1999-10-26 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
WO1997012623A1 (en) * 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
US5827876A (en) * 1996-04-09 1998-10-27 American Home Products Corporation Inhibition of bone loss by 3-(4-acrylamidobenzoyl) benzo b!-thiophenes
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6488940B2 (en) * 1997-08-21 2002-12-03 Johnson & Johnson Consumer Companies, Inc. Use of 17-α-estradiol for the treatment of aged or sundamaged skin and/or skin atrophy
US20040044080A1 (en) * 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
HUP0200871A3 (en) 1999-05-04 2004-04-28 Strakan Int Ltd Androgen glycosides and androgenic activity thereof
US6245819B1 (en) 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
IL145838A (en) * 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis
US7906480B2 (en) * 2002-05-23 2011-03-15 Michael Holick Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
PT1509215E (pt) * 2002-06-06 2007-01-31 Hormos Medical Ltd Tratamento ou profilaxia da atrofia urogenital e seus sintomas em mulheres
JP5193196B2 (ja) 2006-06-02 2013-05-08 ペア ツリー ウーマンズ ヘルス ケア 萎縮性膣炎の治療の方法
US8097660B2 (en) * 2006-08-31 2012-01-17 Bayer Materialscience Llc Rigid polyurethane foams with low thermal conductivity and a process for their production
US20080139513A1 (en) * 2006-09-26 2008-06-12 Novavax, Inc. Transdermal deliver of active agents
WO2008099060A2 (en) 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
EP2821385B1 (en) 2007-02-14 2016-07-27 Hormos Medical Ltd. Method for the preparation of therapeutically valuable triphenylbutene derivatives
US9321712B2 (en) 2012-10-19 2016-04-26 Fermion Oy Process for the preparation of ospemifene
ES2965820T3 (es) 2015-06-01 2024-04-17 Durga Entpr Llc Composiciones para tratamiento de vaginitis atrófica, dispareunia perimenopáusica y posmenopaúsica y/o mujeres ooforectomizadas y métodos de tratamiento con las mismas
EP3498276B1 (en) * 2017-12-14 2020-09-23 Disproquima, S.A. Ectoine and ectoine derivatives for use in vulvovaginal conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
WO1993010742A2 (en) * 1991-11-27 1993-06-10 Novo Nordisk A/S Chemical compounds, their preparation and use

Also Published As

Publication number Publication date
ES2153851T3 (es) 2001-03-16
JPH07215860A (ja) 1995-08-15
EP0664124A1 (en) 1995-07-26
RU94044436A (ru) 1996-10-20
US5461064A (en) 1995-10-24
KR950016732A (ko) 1995-07-20
CN1108097A (zh) 1995-09-13
EP0664124B1 (en) 2001-02-14
CA2138511A1 (en) 1995-06-22
ZA9410078B (en) 1996-06-19
NZ270173A (en) 1996-08-27
RU2143897C1 (ru) 2000-01-10
AU699948B2 (en) 1998-12-17
US5610167A (en) 1997-03-11
IL112041A0 (en) 1995-03-15
PH31600A (en) 1998-11-03
DE69426690T2 (de) 2001-08-09
HU9403655D0 (en) 1995-02-28
AU8154294A (en) 1995-06-29
HUT71221A (en) 1995-11-28
CZ321594A3 (en) 1995-09-13
DE69426690D1 (de) 2001-03-22
NO944919D0 (no) 1994-12-19

Similar Documents

Publication Publication Date Title
NO944919L (no) Fremgangsmåte for å inhibere atrofi av huden eller vagina
MY132056A (en) Methods of inhibiting physiological conditions associated with an excess of neuropeptide y.
NO944914L (no) Fremgangsmåte for å inhibere autoimmunsykdommer
NO944927L (no) Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom
NO973635L (no) Fremgangsmåte for hemming av celle-celle adhesjon
DE69427800T2 (de) Methode zur Hemmung der Endometriose
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
MX9701329A (es) Metodos para la inhibicion de la replicacion viral.
ATE216582T1 (de) Hemmung uteriner fibrose
DK0659416T3 (da) Inhibering af seborE og acne
NO944926L (no) Fremgangsmåter for å inhibere myeloperoksidaseaktivitet
NO944930L (no) Hemming av dysfunksjonell uterin blödning
NO944924L (no) Fremgangsmåter for inhibering av Turner's syndrom
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
DK0662325T3 (da) Inhibering af ovariedysgenese, forsinket pubertet eller sexuel infantilisme
WO1995001170A3 (en) Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders
NO944931L (no) Anvendelse av 2-fenyl-3-aroylbenzotiofener for inhibering av tidlig seksuell modenhet
NO975580L (no) Fremgangsmåte for å inhibere melanom
NO973367L (no) Fremgangsmåte for å inhibere miljömessige östrogen
NO973609L (no) Fremgangsmåte for å inhibere effektene av IL-6
NO971794L (no) Fremgangsmåte for hemming av tilstander forbundet med bradykinin
NO971029L (no) Fremgangsmåter for hemming av endometriale metoser
NO944909L (no) Fremgangsmåter for inhibering av mannlig infertilitet
NO944910L (no) Fremgangsmåte for å inhibere obsessive-kompulsive tilstander og spiseforstyrrelser
MX9701333A (es) Metodos para inhibir el daño neuronal.